Table 4 Overview of response criteria for lymphoma
From: PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Criteria (year) [reference] | Categories | |||
|---|---|---|---|---|
Complete response | Partial response | Stable disease | Progressive disease | |
Lugano (2014) [40] | • CT: reduction of lesions to normal size • PET: normalised 18F-FDG-uptake (DS 1–3) | • CT: ≥ 50% reduction in SPD of up to 6 lesions • PET: reduced 18F-FDG- uptake (DS 4 or 5) | • CT: neither sufficient change for PD nor PR • PET: unchanged 18F-FDG-uptake (DS 4 or 5) | • CT: ≥ 50% increase in SPD of lesions • New lesion(s) • PET: increased 18F-FDG-uptake (DS 4 or 5) or new 18F-FDG-avid lesions |
LYRIC (2016) [41] | • Same as Lugano | • Same as Lugano | • Same as Lugano | Adapted from Lugano to indeterminate response (IR) categories: • IR1: ≥ 50% increase in SPD in 12 weeks without clinical deterioration • IR2: < 50% increase in SPD with new lesion(s), or ≥ 50% increase in SPD of a lesion or set of lesions at any time during treatment • IR3: increase in 18F-FDG-uptake without increase in lesion size meeting criteria for PD |
RECIL (2017) [42] | • CT: complete disappearance of all TL and all nodes with LD < 10 mm • PET: normalised 18F-FDG-uptake (DS 1–3) | Partial response • CT: ≥ 30% decrease in SLD of TL, but no CR • PET: DS 4 or 5 | • CT: < 10% decrease or ≤ 20% increase SLD of TL • PET: any DS | • CT: > 20% increase in SLD of TL • For small lymph nodes < 15 mm after therapy, a minimum absolute increase of 5 mm and the LD > 15 mm • New lesion(s) • PET: any DS |
Minor response • Same as PR yet only ≥ 10% and < 30% SLD decrease | ||||